

## SAMPLE CODING

### Non-small Cell Lung Cancer (NSCLC)

| TYPE  | CODE          |               | DESCRIPTION  |
|---|---------------|---------------|--|
| Diagnosis: ICD-10-CM  | C33           |               | Malignant neoplasm of trachea                              |
|   | C34.00–C34.02 |               | Malignant neoplasm of bronchus and lung; main bronchus     |
|   | C34.10–C34.12 |               | Malignant neoplasm of bronchus and lung; upper lobe        |
|   | C34.2         |               | Malignant neoplasm of bronchus and lung; middle lobe       |
|   | C34.30–C34.32 |               | Malignant neoplasm of bronchus and lung; lower lobe        |
|   | C34.80–C34.82 |               | Malignant neoplasm of bronchus and lung; overlapping sites |
|   | C34.90–C34.92 |               | Malignant neoplasm of bronchus and lung; unspecified part  |
| Drug: NDC   | 10-digit      | 11-digit      |  |
| Note: Payer requirements regarding use of a 10-digit or 11-digit NDC may vary. Both formats are listed here for your reference. | 50242-130-01  | 50242-0130-01 | 150 mg (240 capsules)                                      |

ICD-10-CM=International Classification of Diseases, 10th Revision, Clinical Modification; NDC=National Drug Code.

These codes are not all-inclusive; appropriate codes can vary by patient, setting of care and payer. Correct coding is the responsibility of the provider submitting the claim for the item or service. Please check with the payer to verify codes and special billing requirements. Genentech does not make any representation or guarantee concerning reimbursement or coverage for any service or item.

Many payers will not accept unspecified codes. If you use an unspecified code, please check with your payer.

ALECENSA® is a registered trademark of Chugai Pharmaceutical Co., Ltd., Tokyo, Japan.  
The Access Solutions logo is a registered trademark of Genentech, Inc.

Please see Important Safety Information in full [Prescribing Information](#).